On August 1, 2016 GenSpera, Inc. (OTC/QB: GNSZ), a clinical-stage biotechnology company developing a novel prodrug therapeutic for the treatment of cancer, reported that it will change its corporate name to Inspyr Therapeutics, Inc. and will begin trading on OTC/QB under the ticker symbol NSPX effective August 2, 2016 (Press release, GenSpera, AUG 1, 2016, View Source [SID:1234514164]). The Company will also unveil a new corporate website at www.inspyrtx.com. Schedule your 30 min Free 1stOncology Demo! "The changing of our corporate name is a first step in a number of upcoming actions that will define our path forward and our focus on building shareholder value," said Peter E. Grebow, Ph.D., Interim Chairman. "Our new corporate name, Inspyr Therapeutics, reflects the significant potential we see with the novel prodrug mipsagargin and our Company’s future potential."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!